Kangmei Pharmaceutical Co., Ltd. provided earnings guidance for the year 2019. For the year, the company predicts that it will suffer a loss in its net profit belonging to shareholders of the listed company in 2019 compared with the same period of the year before for the first time, with the net profit belonging to shareholders of the listed company to be between RMB 1.35 billion and RMB 1.65 billion. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 2.10 billion and RMB 2.40 billion.